Dibikor tab 500mg 60 pieces

Description

Composition
Active substance:
1 tablet contains: 500 mg of taurine.
Excipients:
Cellulose microcrystalline 46 mg Potato starch 36 mg gelatin 12 mg, colloidal silicon dioxide (Aerosil) 0.6 mg Calcium stearate 5.4 mg.
Description:
Tablets white or almost white, round shape, Valium, with the mark and chamfered.
Product form:
Tablets of 500 mg. 10 tablets in blisters of PVC film and aluminum foil. 3 or 6, the contour of cellular packaging together with instructions for use placed in a pile of cardboard.
Contraindications
Hypersensitivity to the drug. Age 18 years (effectiveness and safety have been established). If you have one of the following conditions before taking the drug should consult a doctor.
Dosage
500 mg
Indications
Type 2 diabetes, including moderate hypercholesterolemia; type 1 diabetes; heart failure of different etiologies; intoxication caused by cardiac glycosides; as a hepatoprotective in patients treated with anti-fungal medications.
Interaction with other drugs
Dibikor® may be used with other drugs; It enhances the inotropic effect of cardiac glycosides.
Overdose
Data on overdose are not available.
pharmachologic effect
Pharmacological group:
Metabolic means.
Pharmacodynamics:
Taurine is a natural product of the sulfur-containing amino acid metabolism: cysteine, cysteamine, methionine. Taurine has osmoregulatory and membrane properties, positively affects the phospholipid composition of cell membranes, normalizes the exchange of calcium and potassium ions in the cells. At taurine identified properties inhibitory neurotransmitter, it has anti-stress effect, can control the release of gamma-aminobutyric acid (GABA), adrenaline and other hormones prolactin, but also to regulate their answers. By participating in the synthesis of proteins in the respiratory chain of mitochondria, taurine regulates oxidative processes and exhibits antioxidant properties; effect on enzymes such as cytochromes, involved in the metabolism of various xenobiotics. Dibikor® improves metabolic processes in the heart, liver and other organs and tissues. In chronic diffuse liver diseases Dibikor® increases blood flow and reduces the severity of cytolysis. Treatment with Dibikor® in cardiovascular disease (CCH) leads to a decrease of stagnation in the small and large circles circulation: reduced intracardiac diastolic pressure, increasing myocardial contractility (maximum speed of contraction and relaxation, contractility index and relaxation time). The drug is moderately reduce blood pressure (BP) in patients with hypertension and has virtually no effect on blood pressure in patients with cardiovascular failure with low blood pressure. Dibikor® reduces side effects arising from overdosage blockers, cardiac glycosides and “slow” calcium channel; decreases hepatotoxicity antifungal agents. Increases efficiency at heavy physical exertion. In diabetes approximately 2 weeks after the beginning of reception Dibikor® drug decreases in blood glucose concentration. It is also noticed significant reduction of triglyceride concentration, to a lesser extent – cholesterol concentration, reduction in atherogenic plasma lipids. With long-term use of the drug (about 6 months) improvement of microcirculatory blood flow observed eye.
Pharmacokinetics:
After a single 500 mg dose Hour Dibikor® active substance taurine 15-20 minutes determined in the blood, reaching a peak after 1.5-2 hours. Fully drug appears in a day.
Pregnancy and breast-feeding
It is not recommended to use the drug during pregnancy and breastfeeding period due to lack of clinical experience in these patients.
Conditions of supply of pharmacies
Without a prescription.
side effects
Allergic reactions to the drug. If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
In patients receiving the drug should Dibikor® reduce the dose of cardiac glycosides sometimes 2 times, depending on the sensitivity of patients to cardiac glycosides. The same rule applies to the blockers “slow” calcium channels. In the absence of reduction or weighting of symptoms, contact your doctor. Do not exceed the maximum term and recommended dose without approval from your doctor.
Effects on ability to drive vehicles, mechanisms of drug does not affect the performance of potentially hazardous activities that require high concentration and psychomotor speed reactions (vehicle control, work with moving machinery, the work manager, operator and so on. D.).
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children.
Dosing and Administration
The drug is taken orally, 20 minutes before a meal. In type 2 diabetes, including moderate hypercholesterolemia: 500 mg (1 tablet), 2 times a day in monotherapy or in combination with other hypoglycemic agents for oral administration, the duration of the course – on the doctor’s recommendation. In type 1 diabetes: 500 mg (1 tablet), 2 times a day in combination with insulin therapy for 3-6 months. When cardiovascular disease: 250-500 mg (1 / 2-1 tablet) 2 times per day treatment – 30 days. The dose may be increased to 2-3 g (4-6 tablets) per day. When cardiac glycoside intoxication: not less than 750 mg (1.5 tablets) per day. As hepatoprotector: 500 mg (1 tablet), 2 times a day for the entire course Hour antifungal agents.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist